Immunobiology and immunotherapy in genitourinary malignancies.

@article{Tsiatas2016ImmunobiologyAI,
  title={Immunobiology and immunotherapy in genitourinary malignancies.},
  author={Marinos Tsiatas and Petros Grivas},
  journal={Annals of translational medicine},
  year={2016},
  volume={4 14},
  pages={270}
}
Immunotherapy has traditionally been a critical component of the cancer treatment armamentarium in genitourinary (GU) cancers. It has an established role in the management of carefully selected patients with metastatic renal cell carcinoma (RCC) [e.g., high dose interleukin-2 (IL-2)] and non-muscle invasive bladder cancer (NMIBC) [e.g., intravesical Bacillus Calmette-Guérin (BCG)]. In 2010, the sipuleucel-T vaccine was approved by the FDA for the management of metastatic castration-resistant… CONTINUE READING
6 Citations
79 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 79 references

Phase II trial of gemcitabine + cisplatin + ipilimumab in patients with metastatic urothelial cancer

  • MD Galsky, NM Hahn, C Albany
  • J Clin Oncol
  • 2016
1 Excerpt

Safety, clinical activity, and PD-L1 expression of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic urothelial carcinoma from the JAVELIN Solid Tumor phase Ib trial

  • AB Apolo, JR Infante, O Hamid
  • J Clin Oncol
  • 2016
1 Excerpt

Similar Papers

Loading similar papers…